Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 743 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary; Hypertension Clear all
Recruiting Phase 3 Interventional

PAH Exercise Study

NCT06941441
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Exercise Therapy
Interventions
Home exercise program
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 6, 2026, 5:57 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

NCT03197688
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Notapplicable
Other
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
105
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 6, 2026, 5:57 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
PF-00489791, placebo, sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

New Orleans Pulmonary Hypertension Biobank

NCT03269630
View directory record Official record
Conditions
Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction, Healthy
Interventions
No intervention. Biospecimen collection only
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 6, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension

NCT04745000
View directory record Official record
Conditions
Hypertension;Pulmonary;Primary
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 6 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

NCT07561034
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization

NCT07224906
View directory record Official record
Conditions
Pulmonary Hypertension, Congestive Heart Failure(CHF), Valve Disease, Heart
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

NCT02911844
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Fulvestrant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 6, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Withdrawn Not applicable Interventional

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT02958358
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Robert Scott Harris, M.D.
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
View directory record Official record
Conditions
Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
Interventions
15N Nitrate, 14N Nitrate
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement

NCT01717209
View directory record Official record
Conditions
Heart Failure
Interventions
Nitric Oxide, Prostacyclin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 6, 2026, 5:57 PM EDT
Completed No phase listed Observational

Heart Disease in Sickle Cell Anemia

NCT00113152
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 5:57 PM EDT
Not listed No phase listed Observational

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716
View directory record Official record
Conditions
Scleroderma, Pulmonary Hypertension
Interventions
No intervention
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
56 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 6, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

NCT06129240
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
LIQ861
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT00678821
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Aerobic exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 82 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Completed No phase listed Observational

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

NCT05776225
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Right heart catheterization (RHC)
Procedure
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • Hartford, Connecticut • Lakeland, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 6, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension

NCT02331225
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary Hypertension, Scleroderma
Interventions
No intervention given
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 6, 2026, 5:57 PM EDT